id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1975-N-0336-0081,FDA,FDA-1975-N-0336,Acknowledgement Letter from CDER to Valeant Pharmaceuticals North America LLC,Other,Acknowledgement Letter/Receipt,2017-10-11T04:00:00Z,2017,10,2017-10-11T04:00:00Z,,2017-11-27T16:57:22Z,,0,0,0900006482bbe15a
FDA-1975-N-0336-0080,FDA,FDA-1975-N-0336,Response Letter from Valeant Pharmaceuticals (Hogan Lovells LLP) to FDA CDER,Other,Letter(s),2017-09-26T04:00:00Z,2017,9,2017-09-26T04:00:00Z,,2017-09-26T18:54:09Z,,0,0,0900006482b7dba4
FDA-1975-N-0336-0079,FDA,FDA-1975-N-0336,"Acknowledgment Letter from FDA CDER to Virtus Pharmaceuticals OPCO II, LLC ( Buchanan Ingersoll & Rooney, PC)",Other,Acknowledgement Letter/Receipt,2017-09-05T04:00:00Z,2017,9,2017-09-05T04:00:00Z,,2017-09-05T18:32:41Z,,0,0,0900006482b03f7f
FDA-1975-N-0336-0078,FDA,FDA-1975-N-0336,"Request for Internal Agency Review from Virtus Pharmaceuticals OPCO II, LLC ( Buchanan Ingersoll & Rooney, PC)",Other,Request,2017-09-05T04:00:00Z,2017,9,2017-09-05T04:00:00Z,,2024-11-07T01:10:44Z,,1,0,0900006482b03f7e